1. Targeting histone modifiers in bladder cancer therapy — preclinical and clinical evidence
   Shiyu Zhang et al, 2024, Nature Reviews Urology CrossRef
2. CORM-3 Attenuates Oxidative Stress-Induced Bone Loss via the Nrf2/HO-1 Pathway
   Chen Jin et al, 2022, Oxidative Medicine and Cellular Longevity CrossRef
3. Tumor-Associated Macrophages in Bladder Cancer: Biological Role, Impact on Therapeutic Response and Perspectives for Immunotherapy
   Marine M. Leblond et al, 2021, Cancers CrossRef
4. Uveal Melanoma Cell Line Proliferation Is Inhibited by Ricolinostat, a Histone Deacetylase Inhibitor
   Husvinee Sundaramurthi et al, 2022, Cancers CrossRef
5. Unraveling the Epigenetic Role and Clinical Impact of Histone Deacetylases in Neoplasia
   Dimitrios Goutas et al, 2021, Diagnostics CrossRef
6. Advanced Bladder Cancer: Changing the Treatment Landscape
   Vladimir Bilim et al, 2022, Journal of Personalized Medicine CrossRef
7. Targeting HDAC6 to Overcome Autophagy-Promoted Anti-Cancer Drug Resistance
   Hyein Jo et al, 2022, International Journal of Molecular Sciences CrossRef
8. Reducing PD-L1 Expression by Degraders and Downregulators as a Novel Strategy to Target the PD-1/PD-L1 Pathway
   Zhijie Wang et al, 2024, Journal of Medicinal Chemistry CrossRef
9. Epigenetic modifications: Critical participants of the PD‑L1 regulatory mechanism in solid tumors (Review)
   Xiaoran Ma et al, 2022, International Journal of Oncology CrossRef
10. PD-L1 Expression in Neoplastic and Immune Cells of Thymic Epithelial Tumors: Correlations with Disease Characteristics and HDAC Expression
    Ioanna E. Stergiou et al, 2024, Biomedicines CrossRef
11. The Potential of Senescence as a Target for Developing Anticancer Therapy
    Hyein Jo et al, 2023, International Journal of Molecular Sciences CrossRef